ClinicalTrials.gg
CompletedNCT06066125Updated Feb 20, 2025

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of AK111 and AK111 in Psoriasis and Skin Diseases, sponsored by Akeso. Completed at 34 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2023, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
48th of 182
351 · median 171
Started
2023
with 27 others
Phase 3
58 of 206
16 open now
Registered
111th of 206
by date
Lead sponsor
8 of 206
Akeso

Among the 206 studies in Psoriasis with a site in China, this one is the 48th largest by enrollment of the 182 interventional ones that give a count, is one of 28 that started in 2023, is one of 58 in phase 3, and was the 111th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis. Subjects will be randomized to receive AK111 or placebo subcutaneously and followed up to week 56.

03

Conditions studied

  • Psoriasis
  • Skin Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥18 years old.
  2. Subjects diagnosed with moderate to severe plaque psoriasis with or without psoriatic arthritis.
  3. At screening and baseline, PASI score ≥ 12 , Body Surface Area(BSA) ≥ 10%, sPGA ≥ 3.
  4. Suitable for systematic therapy assessed by investigators.
  5. Subjects who are women of must have a negative pregnancy test at screening and must be practicing an adequate, medically acceptable method of during the study and for at least 6 months after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Types of psoriasis other than chronic plaque-type psoriasis.
  2. Drug-induced psoriasis.
  3. Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.
  4. Positive results of confirmatory test for , , (HIV) or syphilis.
  5. History of repeated chronic infection, had any serious infection or systemic infection within 2 months before screening.
  6. Progressive or uncontrolled symptoms or signs of circulatory, respiratory, digestive, neuropsychiatric or psychological, hematological, endocrine and other systems before randomization.
  7. History of malignant tumour within 5 years before screening.
  8. Previous or current diseases.
  9. Allergic to any component of the drug, or have had severe allergic reactions to monoclonal antibodies.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    AK111 regimen 1

    Drug: AK111

  • Experimental
    AK111 regimen 2

    Drug: AK111

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAK111

    AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

  • DrugAK111

    AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

  • DrugPlacebo

    Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.

06

What researchers measure

Primary outcomes

  1. The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.

    PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%),and severity is estimated by clinical signs, erythema, induration and desquamation: scale 0 (none) to 4 (maximum).Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2, body: 0.3,legs: 0.4).PASI 50, PASI75 and PASI 90 were defined as participants achieving \>= 50%, \>= 75% or \>= 90% improvement from baseline, respectively.The sPGA is an instrument providing a subjective evaluation of the overall severity of psoriasis, based on severity of induration, scaling, and erythema. The scores are: 0 = clear; 1 = minimal; 2 = mild; 3 = moderate; 4 = marked; 5 =severe.

    Time frame: at week 12

Secondary outcomes

  1. The percentage of subjects who achieved at least 90% reduction in PASI score from baseline (PASI 90) at week 12.

    Time frame: at week 12

  2. The percentage of subjects who achieved PASI 75 and the percentage of subjects who achieved sPGA 0/1 at week 52.

    Time frame: at week 52

07

Study locations

34 sites
  • The first affiliated hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • The first affiliated hospital of wannan medical college
    Wannan, Anhui, China
  • Affiliated hospital of Chongqing Three Gorges Medical College
    Chongqing, Chongqing, China
  • Chongqing traditional Chinese medicine hospital (Daomenkou branch)
    Chongqing, Chongqing, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Shenzhen People's hospital
    Shenzhen, Guangdong, China
  • The first affiliated hospital of Hainan Medical university
    Haikou, Hainan, China
  • Nanyang First People's hospital national third class a hospital
    Nanyang, Henan, China
  • Renmin hospital of Wuhan University Hubei general hospital
    Wuhan, Hubei, China
  • Yichang central People's hospital
    Yichang, Hubei, China
  • The third Xiangya hospital of Central South University
    Changsha, Hunan, China
  • The frist People's hospital of Lianyungang
    Lianyungang, Jiangsu, China
  • Dermatology Hospital of China Union Medical University
    Nanjing, Jiangsu, China
  • The affiliated hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • Yancheng No.1 People's hospital
    Yancheng, Jiangsu, China
  • Dermatology hospital of Jiangxi province
    Nanchang, Jiangxi, China
  • The second hospital of Dalian Medical University
    Dalian, Liaoning, China
  • Second hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Tangdu hospital of the Fourth Military Medical University
    Tanggu, Shanxi, China
  • West China school of medicine, West China hospital of Sichuan University
    Chengdu, Sichuan, China
  • Tianjin academy of traditional Chinese medicine affiliated hospita
    Tianjin, Tianjin, China
  • Tianjin Medical University general hospital
    Tianjin, Tianjin, China
  • Hangzhou first People's hospital
    Hangzhou, Zhejiang, China
  • The first hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • Ningbo Huamei hospital, University of Chinese Academy of Sciences
    Ningbo, Zhejiang, China
  • The first affiliated hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • Beijing friendship hospital, Capital Medical University
    Beijing, China
  • Peking University third hospital
    Beijing, China
  • Guangdong provincial people's hospital
    Guangdong, China
  • Affiliated hospital of Chengde Medical University
    Hebei, China
  • The second affiliated hospital of Harbin Medical University
    Heilongjiang, China
  • Xiangya hospital Central South University
    Hunan, China
  • Huashan hospital, Fudan University
    Shanghai, China
  • Shanghai skin disease hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2024, 16 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Mar 31, 2023
Primary completionActual
Aug 19, 2024
CompletionActual
Aug 19, 2024
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066125
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Mar 31, 2023
Primary completion
Aug 19, 2024
Completion
Aug 19, 2024
Last update
Feb 20, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gumokimab

Start the discussion